Putnam Investments’s Trillium Therapeutics Inc. TRIL Stock Holding History

Putnam Investments’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-83,111	Closed	-$470K	–	1304
2016 Q4	$470K	Sell	83,111 -16,889	-17%	-$168K	﹤0.01%	1128
2016 Q3	$1.48M	Hold	100,000	–	–	﹤0.01%	929
2016 Q2	$898K	Hold	100,000	–	–	﹤0.01%	1117
2016 Q1	$925K	Hold	100,000	–	–	﹤0.01%	1128
2015 Q4	$1.26M	Hold	100,000	–	–	﹤0.01%	1101
2015 Q3	$1.3M	Hold	100,000	–	–	﹤0.01%	1104
2015 Q2	$2.18M	Buy	+100,000	New	+$2.28M	﹤0.01%	1033

Other funds holding TRIL

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IBT

International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Putnam Investments's TRIL Position: Q1 2017 in Review

Putnam Investments sold out of Trillium Therapeutics Inc. (TRIL) in Q1 2017, closing a stake of 83,111 shares — an estimated $470K sold.

Putnam Investments first reported a position in TRIL in Q2 2015 and held it in 7 quarters. The position peaked at $2.18M in Q2 2015. 22 funds tracked by Wall St. Rank hold TRIL as of Q1 2017.

Putnam Investments reported no remaining Trillium Therapeutics Inc. position as of Q1 2017 after selling out during the quarter.
Putnam Investments sold 83,111 Trillium Therapeutics Inc. shares in Q1 2017, an estimated $470K.
Putnam Investments first reported a position in Trillium Therapeutics Inc. in Q2 2015 and held it in 7 quarters.
Putnam Investments's Trillium Therapeutics Inc. position peaked at $2.18M in Q2 2015.
22 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q1 2017.

Based on Putnam Investments's 13F filing for Q1 2017, filed 15 May 2017.